Results 221 to 229 of about 15,210 (229)

Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents

Biology of Blood and Marrow Transplantation, 2017
Theodore A Gooley, Brenda M Sandmaier, H Joachim Deeg   +2 more
exaly  

Predictive and prognostic value of gene mutations in myelodysplastic syndrome treated with hypomethylating agents: a meta-analysis

Leukemia and Lymphoma, 2022
exaly  

When is the optimal timing for allogeneic transplantation in the case of MDS patients treated with hypomethylating agents?

Expert Review of Hematology, 2013
Joon-Ho Moon
exaly  

Do hypomethylating agents prevent relapse after Allo-HCT?

Advances in Cell and Gene Therapy, 2018
Thomas Schroeder, Christina Rautenberg, Rainer Haas, Ulrich Germing, Guido Kobbe   +4 more
openaire   +1 more source

Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia

Biology of Blood and Marrow Transplantation, 2016
Piyanuch Kongtim, Uday R Popat, Sameh Gaballa   +2 more
exaly  

Results of Treatment With Hypomethylating Agents Versus Hypomethylating Agents/Venetoclax in Patients With AML Single-Center Experience

Clinical Lymphoma Myeloma and Leukemia
Ana Flavia Patiño, Erika Brulc, Alberto Gimenez Conca   +2 more
openaire   +1 more source

Hypomethylating agents in myelodysplastic syndromes.

Clinical advances in hematology & oncology : H&O, 2012
openaire   +1 more source

AML-032 Results of Treatment With Hypomethylating Agents Versus Hypomethylating Agents/Venetoclax in Patients With AML Single-Center Experience

Clinical Lymphoma Myeloma and Leukemia
Ana Flavia Patiño, Erika Brulc, Alberto Gimenez Conca   +2 more
openaire   +1 more source

Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience

Frontiers in Oncology
exaly